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Abstract: The notion that vitamin D can influence the incidence of cancer arose from 
epidemiological studies. The major source of vitamin D in the organism is skin production upon 
exposure to ultra violet-B. The very first observation of an inverse correlation between exposure of 
individuals to the sun and the likely hood of cancer was reported as early as 1941 [1]. In 1980, 
Garland and Garland hypothesised from findings from epidemiological studies of patients in the 
US with colon cancer that vitamin D produced in response to sun exposure is protective against 
cancer as opposed to sunlight per se [2]. Later studies revealed inverse correlations between sun 
exposure and the occurrence of prostate [3] and breast [4] cancers. These observations prompted 
laboratory investigation of whether or not vitamin D had an effect on cancer cells. Vitamin D is not 
active against cancer cells, but the most active metabolite 1α,25-dihydroxyvitamin D3 (1,25D) has 
profound biological effects. Here we review the anticancer action of 1,25D, clinical trials of 1,25D to 
date and the prospects of the future therapeutic use of new and low calcaemic analogues. 
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1. Introduction 
Differentiation of mouse myeloid leukemia cell line towards macrophage-like cells in response 
to a sub-nanomolar concentration of 1α,25-dihydroxyvitamin D3 (1,25D) was reported in 1981 [5]. 
The changes observed were striking; the leukemic cells exposed to 1,25D not only looked different, 
but were also able to phagocytose, produce antibacterial agents, migrate and adhere to substratum 
[5]. A similar effect of 1,25D on human acute myeloid leukemia (AML) cells was reported soon after 
[6]. In this case, changes in cell cycle progression were observed to accompany differentiation to 
monocytes. The changes were a transient increase in the proportion of cells in the G2/M phase of cell 
cycle, followed by an arrest in the G1/G0 phase [7]. In other words, 1,25D provides an initial signal for 
cell proliferation, followed by different signal leading to cell maturation and cycle arrest [8]. This 
complicated set of events, which is triggered by 1,25D, requires the coordinated actions of signalling 
molecules and transcription factors.  
2. 1α,25-Dihydroxyvitamin D3 -driven cell signalling in AML cells 
It’s widely accepted that expression of a functional vitamin D receptor (VDR) within AML cells 
is required for 1,25D to exert its biological effects [9]. In support of this viewpoint is that AML cells 
which express VDR at a low level are resistant to the differentiating effects of 1,25D, and the 
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sensitivity of AML cells to 1,25D is restored when the level of VDR is upregulated [10]. That the 
presence of VDR is essential to the differentiating action of 1,25D was confirmed by the finding that 
normal blood progenitor cells from VDR knockout mice failed to differentiate into monocytes in 
response to 1,25D [11].  
VDR is a ligand-activated transcription factor that controls the transcription of hundreds of 
genes, either directly or indirectly [12]. Among the VDR-target genes are ones that encode the 
functional attributes of mature macrophages, such as cluster of differentiation (CD) 14 [13], and 
genes that control cell cycle progression are 1,25D responsive [14]. VDR protein is translated in the 
cytosol, and its site of transcriptional activity is the cell nucleus. Therefore, efficient nuclear 
translocation of VDR is prerequisite for its activity and AML cells in which nuclear transport of VDR 
is hampered do not differentiate when treated with 1,25D [15]. AML-associated chromosome 
translocation products, such as promyelocytic leukaemia (PML)/retinoic acid receptor α (RARα), 
promyelocytic leukaemia zinc finger protein (PLZF)/RARα, and AML-1/eight-twenty one protein 
(ETO), may block transport of VDR to the nucleus and reduce the capacity of AML cells to 
differentiate in response to 1,25D [16]. 
However, activation of VDR’s transcriptional activity is not sufficient to explain all of the 
actions of 1,25D against AML cells. Hours are required for 1,25D to result in VDR-mediated 
transcription of gene products and some of the biological effects of 1,25D observed within AML cells 
happen in minutes. As to immediate effects in AML cells, 1,25D activates protein kinase C (PKC) 
[17], the extracellular-signal activated kinases (Erk) 1 and 2 [18] and the phosphatidyl inositol 
3-kinase (PI3K) [19]. Additionally, 1,25D activates lipid signalling pathways in AML cells. These are 
important to 1,25D-driven cell differentiation as it has been shown that inhibition of phospholipase 
D (PLD) blocks 1,25D-induced AML cells differentiation [20]. Enzymatic activity of PLD leads to the 
breakdown of membrane phospholipids, such as phosphatidylcholine and produces a second 
messenger, diacylglycerol (DAG). DAG in turn is an activator of the classical isoforms of PKC, which 
have been shown to be rapidly activated by 1,25D [17] and are on the pathway leading to activation 
of Erk1,2 [18]. Another lipid signalling enzyme that is activated in AML cells in response to 1,25D is 
phospholipase A2 (PLA2) [21]. Activation of PLA2 starts as early as 3 hours and lasts at least for 48h 
post-exposure of cells to 1,25D. Experiments using inhibitors of PLA2 have shown that 
1,25D-induced differentiation is enhanced when the activity of PLA2 is inhibited. These experiments 
suggested that the end-products of the PLA2 metabolic pathway provide a negative feedback to the 
action of 1,25D [22,23].  
The mechanism whereby immediate signal events are provoked is still not entirely clear [24] as 
a number of mechanisms have been proposed to explain this phenomenon. One hypothesis is that a 
small portion of classical VDR is localized at the plasma membrane and 1,25D binds to an alternative 
ligand binding pocket to activate signal transduction from the cell membrane [25]. An alternative 
viewpoint is the existence of a membrane receptor for 1,25D that is distinct from VDR and is 
responsible for the rapid actions of 1,25D. Such a receptor has been shown to be expressed by 
intestine cells and is termed Membrane Associated Rapid Response Steroid-binding (MARRS) 
protein, which is also known as ERp57 or protein disulfide-isomerase A3 (PDIA3) [26,27]. Whether 
this receptor is present in AML cells has not been determined. 
A primary feature of AML cells is their uncontrolled proliferation. In patients, the leukemic 
blast cells outnumber other blood cells. Moreover, the cells accumulating are non-functional because 
of a block at an early stage of myeloid cell differentiation. The use of 1,25D to inhibit the proliferation 
of AML cells and drive differentiation of these cells towards macrophages would be beneficial to 
patients or, at least, make their disease bearable. Additionally, AML patients are deficient in innate 
immune responsiveness and are prone to infection; restoration of some macrophage-related 
immunity might be beneficial. Unfortunately, there is a major drawback to the use of 1,25D as an 
anticancer agent and achievement of an effective therapeutic dose. The primary role of 1,25D is to 
regulate calcium and phosphate homeostasis, and when 1,25D is administered to patients at a high 
dose there are undesirable calcaemic effects. Serious side effects arising from hypercalcaemia 
include coma and cardiac arrest. The intermittent use of a high dose of 1,25D in patients with 
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advanced prostate cancer has been reported to be safe. However, the addition of 1,25D to 
dexamethasone treatment did not significantly improve the response rate [28]. The principle strategy 
to overcoming the problem of calcaemic effects has been the development of analogues of 1,25D 
with the desired anticancer effect without being calcaemic. Numerous analogues of 1,25D that have 
negligible calcaemic action have been synthesized [29,30]. Interestingly, neither the calcaemic nor 
the anti-proliferative potentials of analogues of 1,25D analogues can be correlated directly to their 
affinities to VDR [30]. 
3. The actions of 1α,25-dihydroxyvitamin D3 against carcinomas 
The hypothesis that vitamin D deficiency is a risk factor in terms of the development of prostate 
cancer was proposed in 1990 [31]. Schwartz and Hulka proposed that an appropriate level of vitamin 
D is essential to maintain the normal phenotype of prostate cells. Soon after, investigators 
documented the presence of VDR in prostate cells [32]. Later, epidemiological studies showed that 
serum levels of 25-hydroxyvitamin D3 (25D) adversely correlate with prostate cancer risk [33]. This 
was most obvious in men living at a  high latitude, for example,  in Scandinavia, whose 25D level 
in blood serum was very low, below 16 ng/ml [34]. Numerous publications followed which 
documented that 1,25D has a beneficial action against prostate cancer cells. 1,25D was observed to 
inhibit proliferation, stimulate apoptosis, and interestingly have an anti-inflammatory effect 
towards VDR-positive prostate cancer cells [35]. These influences were accompanied by a decrease 
in the capacity of prostate cancer cells to migrate and, accordingly, their invasive potential [36,37]. A 
most surprising observation was that prostate cells have the capacity to convert biologically inert 
25D into biologically active 1,25D. Previously, the only organ that was thought to be able to 
hydroxylate 25D to 1,25D was the kidney. In 1998 it was shown that normal prostate cells also 
possess the 1-α-hydroxylase to 25D (CYP27B1), which provides prostate cells with the means to 
synthesize 1,25D [38]. The activity of CYP27B1 has been examined in relation to the progressive 
steps of prostatic neoplasia, and the activity of CYP27B1 diminishes as cells progress from a normal 
phenotype, through hyperplasia to a malignant phenotype [39]. Other studies have provided data to 
further support the notion that a correct level of vitamin D and its autocrine conversion to 1,25D in 
the prostate are protective factors in prostate neoplasia. A high dietary intake of calcium has also 
been found to correlate with prostate cancer incidence [40] and this has substantially complicated 
the picture as a high level of circulating 1,25D increases the uptake of calcium from the intestine. An 
understanding of the role of 1,25D in prostate neoplasia is as yet incomplete but that 1,25D plays an 
important role in the development of prostate and prostate cancer is not questioned. 
A large proportion of breast cancer cells contain the VDR protein, however the level of 
expression is variable within individual cells [41] and, therefore, the biological response to 1,25D 
varies for an individual patient’s cells and between patients. The primary effect of exposure of breast 
cancer cells to 1,25D is cell cycle arrest due to changes in the functional status of the proteins that 
regulate cell cycle, such as retinoblastoma protein (Rb) and cyclin-dependent kinases and their 
inhibitors [42]. The induction of apoptosis is mediated by a reduction in the level of bcl-2 and 
up-regulation of the level of p53 [43]. An effect of 1,25D on cell proliferation is also mediated in a 
secondary way, via interference to the function of estrogen receptors (ER). 1,25D and its analogues 
down-modulate the expression of ERα, which in turn reduces the level of mitogenic signals to breast 
cancer cells from estrogens [44]. Another mechanism of the anticancer action of 1,25D against breast 
cancer cells is that it down-regulates the expression of aromatase, which catalyses a step in estrogen 
synthesis [45]. One of the key factors in regard to the activity of 1,25D is its availability in breast 
cancer environment. This is maintained by the balance between synthesis and catabolism. CYP27B1 
is present in some breast cancer cells, to control the autocrine synthesis of 1,25D, but this enzyme is 
also active in breast cancer microenvironment. It has been shown that breast adipocytes produce 
CYP27B1, bio-activate 25D to 1,25D and in a paracrine fashion deliver 1,25D to the breast epithelium 
[46]. On the other hand, the availability of 1,25D is maintained by its degradation. This process is 
maintained by the 24-hydroxylase of 1,25D (CYP24A1). In normal tissues this enzyme is expressed in 
response to 1,25D exposure, providing a regulatory mechanism that maintains the concentration of 
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1,25D at a desired level [47]. Genome hybridization studies have revealed that in certain human 
breast cancers the CYP24A1 gene is amplified and this may cause a reduction in the level of 1,25D 
level and cells to proliferate unduly [48]. 
As mentioned above, an inverse correlation between the incidence malignancy and the level of 
vitamin D was first observed for colon cancer [2]. In vitro studies have shown that 1,25D and its 
analogues are able to inhibit the proliferation of colon cancer cells [49]. The anti-proliferative effect of 
1,25D is revealed by an accumulation of cells in the G0/G1 phase of the cell cycle, and this is caused 
by an enhanced expression of cyclin-dependent kinase inhibitors p21CIP1 and p27KIP1 and reduced 
expression of cyclin A and cyclin F [50]. In addition, 1,25D sensitizes colon cancer cells to 
pro-apoptotic signals, through up-regulation of the pro-apoptotic and the down-regulation of the 
anti-apoptotic proteins [50]. Many studies have revealed that 1,25D promotes differentiation of 
colon cancer cells. This has been measured in terms of an expression of brush border enzymes and 
adhesion molecules, which confer the proper structure of colon epithelium, and acquisition of 
phenotypic features such as the presence of microvilli and cells having a polarized structure [50]. As 
for breast cancer, the vitamin D metabolic pathways appear to be important to colon tumorigenesis. 
CYP27B1 expression is enhanced in high- to medium-differentiated human colon tumours as 
compared to tumour-adjacent normal mucosa or colon mucosa from non-cancer patients. In 
high-grade undifferentiated tumour areas expression of  CYP27B1 is decreased [51]. In contrast and 
in the majority of colon adenocarcinomas, expression of the 1,25D degrading enzyme CYP24A1 is 
enhanced [52]. Moreover, the CYP24A1 gene locus has been shown to be amplified in the majority of 
colorectal cancers and this gene has been proposed to be an oncogene [53]. 
4. 1α,25-dihydroxyvitamin D3 and anticancer immunity 
1,25D may be used as an anticancer agent alone and in combination with chemotherapeutic 
drugs as a means of enhancing the potency of such. As to the latter use, patients receiving 
chemotherapy are highly vulnerable to infections which can lead to death. Therefore it is important 
to ensure that 1,25D and new analogues are beneficial to good health and particularly do not have a 
damaging effect on the patient’s immune system. In essence, an appropriate level of 1,25D is 
essential for good health and as to the correct function of the innate and adaptive immune systems.   
The ancient Greeks first observed the benefit of exposure to sunlight, and presumably the 
synthesis of 1,25D, to good health. They used heliotherapy to treat the disease we now know as 
tuberculosis (TB). In 1903 Niels Finsen won the Nobel Prize for showing that exposure to ultra-violet 
light could be used to treat cutaneous TB. The need to promote public awareness of the importance 
of vitamin D to good health stems from knowledge of the consequences of vitamin D deficiency. A 
low systemic level of 1,25D leads to a higher risk of chronic diseases that affect a variety of organs. 
Such include diabetes [54], hypertension [55], inflammatory bowel disease  [56] and kidney disease 
with a poor outcome at late stage [57]. Vitamin D also protects against osteoporosis [58], delays the 
onset of type 1- and 2-diabetes [54] and lowers the blood pressure in hypertensive animals [59]. 
There is the possibility that the association studies are revealing that 25D is a marker of poor 
health/lifestyle in general. Even so, cod liver oil has been used for over 100 years as an excellent 
source of vitamin D and a cure-all supplement, and the American Institute of Medicine recommends 
adequate intake (from UV, diet or supplement) of vitamin D at 600 IU per day up to the age of 70 and 
800 IU if older [60]. 
1,25D enhances the protective effects of the innate immune response. Individuals who are 
vitamin D deficient [61] and those with inactivating mutations in the gene encoding VDR show 
defects in responses towards infectious agents (Etzioni et al., Pediatric Res. 1989, 25: 276-279). 
Tiosano and colleagues examined the immune status of fifteen hereditary vitamin-D resistant 
patients that have a truncated VDR which is unable to bind 1,25D and devoid of function. They 
reported no increased incidence of infectious, or autoimmune, diseases, but there were some 
differences between people with wild type and mutated VDR as to the capacity to mount immune 
responses.  [62]. In keeping, it has been suggested that supplementation of vitamin D can help to 
fight off viral and other infections by boosting the function of the immune system [63,64]. Most of 
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the cells of the immune system express VDR and these cells also have the enzymes to make 1,25D 
from circulating 25D. As such, locally produced 1,25D plays an important role in enhancing the 
status of innate immunity. Blood-derived macrophages express VDR and can make their own 1,25D 
[65]. 1,25D promotes the proliferation and maturation of monocytes and macrophages and the 
migration of these cells to sites of infection. At sites of infection, the recognition of antigens by 
macrophage pattern recognition receptors switches on the production of 1,25D which, in turn, 
stimulates phagocytosis and the expression of the antimicrobial peptides defensin β2 and 
cathelicidin gene product, to increase microbial killing (reviewed in [66]). However, production of 
AMP may not be the only mechanism by which 1,25D controls infection. In a murine model of 
pulmonary TB, bacterial load was unaffected, but granuloma size was increased and interferon γ 
(IFNγ) and tumour necrosis factor (TNF) producing CD4 cells decreased in animals on a high 
vitamin D diet. The reduction in immunopathology was protective against the pathogen and to the 
lung tissue [67]. Antimicrobial peptides such as cathelicidin have been implicated in both inducing, 
via receptors such as FPR2 and cell proliferation, and preventing cancer via direct binding to 
negatively charged membranes of tumour cells and induction of apotosis [68,69]. 
1,25D may be of particular benefit to the immune status of older patients with cancer. With age, 
the immune system senesces and shifts towards an inflammatory profile, termed inflammaging. The 
chronic production of inflammatory cytokines appears to remodel the immune system [70,71]. 
Consequently, auto-immune diseases, such as rheumatoid arthritis, are more prevalent in older 
people [72]. In these disorders B lymphocytes make auto-antibodies with the help of T lymphocytes. 
1,25D can dampen down the activity of the adaptive immune system. For example, in vitro studies 
have shown that 1,25D inhibits the generation of plasma cells, their expression of co-stimulatory 
molecules and the function of regulatory B cells. However, administration of a high dose of vitamin 
D to patients with multiple sclerosis has been shown to not have a substantial effect on B cell 
differentiation, isotype switching or the level of B cell activating factor [73]. Differences between 
findings from in vitro and in vivo studies indicate a more complex scenario and have led to 
speculation that the role of germinal centres in plasma cell production and/or other vitamins and 
hormones interfere with vitamin D-driven effects on B cells (reviewed in [74]). Further work is 
warranted to unravel the subtly of the influence of 1,25D on B cell compartments.  
Resting T lymphocytes do not express VDR but do so after they are activated. 1,25D has been 
shown to inhibit T lymphocyte proliferation and T helper (Th) cells that make interleukin (IL)-17 (Th 
17 cells) and interferon-γ (Th 1 cells). Th 1 and Th 17 cells can mediate immune diseases and these 
diseases are ameliorated by treatment with 1,25D. Th 1 and Th 17 responses are also important to 
host resistance to infectious diseases; 1,25D does not affect these responses. These findings lead to 
the viewpoint that 1,25D is a late regulator of the function of T lymphocytes and this function is 
important when there is chronic activation of T lymphocytes (reviewed in [75]). As to switching 
off/controlling immune responses, 1,25D helps to maintain self-tolerance by skewing the maturation 
of CD4 T lymphocytes away from a Th1 phenotype towards a tolerogenic Th2 or regulatory T cell 
phenotype. In this case, secretion of interferon-γ, IL-17, IL-21 and IL-22 is suppressed and expression 
of forkhead box P3 (FOXP3), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and IL-10 is 
enhanced. Importantly, a low-calcaemic analogue of 1,25D has been used to treat T cells from 
healthy individuals to promote a stable regulatory profile [76]. Dendritic cells, through their 
interaction with T lymphocytes, are responsible for the generation of adaptive immunity and also 
have a tolerogenic role. The presence of 1,25D leads to dendritic cells acquiring tolerogenic 
properties [77]. The maturation of these cells is repressed by 1,25D as to reduced expression of the 
major histocompatibility complex and the costimulatory molecules CD40, CD80 and CD86. Secretion 
of IL-12 is decreased and IL-10 expression is enhanced which contributes to dendritic cells becoming 
tolerogenic in nature (reviewed in [66,78]).  The inhibition of T cell priming by dendritic cells by 
1,25D may be more complex than currently considered. On activation, dendritic cells express a 
truncated CYP27B1 transcript that inhibits the conversion of 25D to active 1,25D, while CYP24A1 
levels were unaffected, leading to reduced autocrine 1,25D. Activation of vitamin D to 1,25D by 
macrophages has no such restraint. The production of 1,25D by macrophages  induces expression of 
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VDR- responsive genes by dendritic cells and inhibits antigen stimulation-driven maturation of 
dendritic cells and dendritic cell-dependent T cell responses.. These data reveal that autocrine and 
paracrine activation of vitamin D are important to the control of dendritic cell function. [79]. Recent 
evidence shows that 1,25D may not directly inhibit the generation of antigen-specific CD4 T cells. In 
animals with experimental autoimmune encephalitis, myelin specific CD4 cells in the blood 
numbers were not affected, but treated animals had significantly decreased disease scores. Such 
antigen-specific cells left the lymph nodes and were present in the circulation but they did not enter 
the brain parenchyma. This was shown to be due to down-regulation of CXCR3, a receptor required 
for entry into the central nervous system (CNS) tissue [80]. 
Studies of VDR knock-out mice have brought to attention that  responsiveness of cytotoxic T 
lymphocytes (CTLs) might be somehow affected by the absence of signals from 1,25D and VDR. 
These mice were able to clear Listeria monocytogenes infection, but slower than wild type 
counterparts, and their CTLs produced less IFNγ [81]. These observations have focused attention on 
the role of 1,25D and VDR in CTL differentiation and cytokine production. A clear picture has still to 
emerge though the link between 1,25D and the incidence and/or severity of CTL-controlled 
infections is not disputable[61]. 
As stated above, low levels of 25D or 1,25D have been associated with disease in many 
autoimmune conditions. However, supplementation studies to date have proved inconclusive as to 
the prevention or control of autoimmune conditions, but this may be due to the dose and type of 
vitamin D used in the various studies [82]. A prospective randomised control trial with high dose 
vitamin D (up to 40,000 IU daily till 28 weeks, then 10,000IU daily for 12 weeks) in patients with 
multiple sclerosis was safe and reduced the relapse rate at 52 weeks [83]. More such randomised 
control trials with increased doses are needed to confirm these findings. 
Many of the above findings as to effects of 1,25D on immune cells indicate the potential of 1,25D 
to restore immune tolerance and prevent the progression of autoimmune disease. The immune 
system of elderly patients with cancer might well be strengthened by the use of 1,25D to enhance the 
maintenance of tolerance, leading tothe avoidance of autoimmune disorders. A conceivable 
down-side to the use of 1,25D to treat patients with cancer is whether any existing immunity to the 
tumour is switched from responsiveness towards a state of tolerance of the tumour cells. The extent 
to which this might occur is unknown and a benefit is most likely as to the anticancer action of 1,25D. 
5. Clinical trials of the use of 1α,25-dihydroxyvitamin D3 in cancer 
5.1. Myelodysplasia (MDS) and AML 
The results from in vitro studies of the activity of 1,25D against AML cell lines [6], 
patient-derived AML blasts [84,85] and pre-clinical tests in mice [86,87] clearly encouraged clinical 
trials. However, neither vitamin D nor its partially or fully active metabolites have proved to be very 
effective in clinical trials. One of the reasons for this failure was the clinical trials were performed on 
small groups of patients, ranging from 1 to 53, and the groups consisted of just MDS or AML 
patients, or patients with both conditions were included [88-97]. Moreover, the vitamin D 
compounds used in the clinical trials varied, as some used 1,25D whilst other trials made use of the 
1,25D precursor 1α-hydroxyvitamin D (1D, alfacalcidol). The doses used also varied, as well as the 
additions of other agents used in the treatments. The best results were observed for combination 
treatments. When MDS patients were treated with 1,25D and 13-cis-retinoic acid, the response rate 
was 52% and the transfusion need was reduced. However, the median survival time was not 
prolonged in these patients [96]. In a study which used 1,25D in combination with cytarabine and 
13-cis-retinoic acid a response, to variable extent, was observed in 58% of patients [97]. Even better 
results were obtained using a combination of 1,25D with cytarabine and hydroxyurea: complete or 
partial responses were observed in 79% of elderly patients with AML [95]. 
5.2. Prostate cancer 
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There were several early clinical trials of the use of vitamin D compounds to treat prostate 
cancer. A pilot study revealed that administration of 2,000 IU of vitamin D daily led to a statistically 
significant delay in the rate of prostate specific antigen (PSA) rise in post-operative patients [98]. 
Another bigger study, conducted on 66 patients, confirmed the above results, and supported 
continuation of clinical trials [99]. In the later clinical study, performed on patients with advanced 
prostate cancer, 1,25D, the active form of vitamin D, was given together with dexamethasone [28]. 
Unfortunately, the response rate to this combination treatment was not seen to be significantly 
higher than when dexamethasone was given alone. However, high-dose intermittent 1,25D plus 
dexamethasone appeared to be safe for patients. The above, and some other encouraging results, 
have led to the development of a formulation of oral high dose 1,25D, named DN-101, by Novacea 
Inc. (San Francisco, CA). This new formulation in combination with docetaxel versus placebo and 
docetaxel was tested in a large, double-blinded, randomized study named ASCENT-1 [100]. The 
primary end-point, which was a PSA response within 6 months of enrolment, was not significantly 
different as to the DN-101 versus placebo arm. However, the median survival, which was not a 
primary endpoint in the trial, was estimated at 24.5 months in the DN-101 arm versus 16.4 months 
for placebo. This large survival advantage led to the next clinical trial, named ASCENT-2 [101]. 
Unfortunately, ASCENT-2 was terminated by Novacea Inc. on November 05, 2007, because of an 
unexpected and unexplained increased death rate in DN-101 arm. 
Caution is warranted with respect to the use of vitamin D compounds to treat prostate cancer as 
the overall role of 1,25D in aggressive prostate cancer, in particular as to anti-inflammatory effects 
and disease pathogenesis and progression, is not well explored (Batai et al., Front Immunol 2016, 
7:53). Additionally, it has been shown that men with high blood levels of 25D are at increased risk of 
developing prostate cancer (Albanes et al., Cancer Epidemiol Biomarkers Prev 2011, 20: 1850-1860). 
5.3. Breast cancer 
Many in vitro and pre-clinical studies have examined the possible use of 1,25D to treat patients 
with breast cancer. Four meta-analyses identified a significant inverse relationship between the 
circulating concentrations of 25D and breast cancer [102-105]. By contrast, the large randomised 
clinical trial WHI showed that administering 400 IU vitamin D and 1000 mg of calcium versus 
placebo to women did not reduce the risk of breast cancer [106]. The finding from Women’s Health 
Initiative (WHI) does not provide support to the use of vitamin D as a prophylactic agent in the case 
of breast cancer. However, better survival among woman diagnosed with breast cancer has been 
reported to be related to vitamin D intake leading to higher concentrations of 25D [105,107]. 
Moreover, an interesting finding emerged from a retrospective review of patients with HER2+ve 
breast cancer who had received chemotherapy with trastuzumab with or without vitamin D 
supplement (10,472 IU/week). Those who had taken the vitamin D supplements experienced 
significantly improved disease-free survival [108]. The conduct of a randomised, double-blind, 
placebo-controlled trial of vitamin D, or its active hormone 1,25D, with chemotherapy or other 
agents, is clearly important to revealing the benefit or otherwise of vitamin D/1,25D to treating 
breast cancer patients. 
5.4. Colorectal cancer 
Colorectal cancer has been a particular area of focus as to epidemiological studies of the role of 
vitamin D in cancer (reviewed in [109]) and pre-clinical studies of the use of 1,25D. As to studies of 
patients with colorectal cancer, there is a high prevalence of vitamin D deficiency among patients 
with stage IV colorectal cancer [110] and other studies support the notions that the formation of new 
adenomas appears not to be inhibited by vitamin D though progression through the carcinogenesis 
pathway and the growth of lesions are influenced by vitamin D [111]. A trial of vitamin D and 
calcium in patients who had had their colorectal adenomas removed did not reduce the risk, over a 
period of 3 to 5 years, of adenomas recurring [112]. However, whether vitamin D and calcium can 
prevent the recurrence of colorectal adenoma is still under investigation in the large, double-blind 
and randomised clinical trial The Vitamin D/Calcium Polyp Prevention Study [113]. The pending 
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results should provide further insight to whether vitamin D can reduce the incidence of adenoma 
recurrence. Hence, there isn’t definitive evidence from patient studies to support vitamin D/1,25D as 
a reliable means to prevent and/or treat colorectal cancer. As brought to attention in a recent article, 
data obtained from studies of colorectal cancer provides the most compelling evidence as to a 
beneficial relationship between intake of vitamin D, and the level of serum 25D, and cancer, but “the 
promise not yet fulfilled” [114]. However, it is important to bear in mind there has been much 
discussion between vitamin D experts on what is a correct level of intake (Brouwer-Brokma et al., 
2012, Osteoporosis Int. 24: 1567-1577). Even so, there has been a long term interest in the use of 
vitamin D/1,25D to treat colorectal cancer and more controlled and randomised trials are needed to 
resolve this matter. 
5.5. Melanoma 
Eighty percent of the daily requirement of vitamin D is made by the skin depending on 
appropriate exposure to sunlight. Melanoma is the most dangerous type of skin cancer and a low 
serum concentration of 25D is associated with both an increased risk of melanoma and unfavourable 
disease  prognosis [115]. Studies have suggested a role for vitamin D in delaying the recurrence of 
melanoma and there are few treatment options for patients with primary cutaneous melanomas that 
are ulcerated and patients with nodal micro-metastases. ANZMTG (Australia and New Zealand 
Melanoma Trials Group) 02.09 Mel-D is an ongoing placebo controlled randomised phase II trial that 
is examining the safety and toxicity of an initial oral and large dose of vitamin D (500,000 IU) 
followed by a monthly oral dose of 50,000 IU for 2 years in patients who have had surgery to excise 
their primary cutaneous melanoma [116]. The findings from this study will be of interest as to the 
possible use of vitamin D, given orally, to treat another hard-to-treat cancer. 
6. The extent to which low calcaemic analogues are in use 
Recently, the result of a phase I multicenter trial in metastatic prostate cancer patients which 
combined the 1,25D analogue inecalcitol with docetaxel-based chemotherapy has been published. 
Inecalcitol is an analogue of 1,25D that shows agonistic activity towards VDR and was well tolerated 
in preclinical studies in mice [117]. The phase I study documented that inecalcitol was well tolerated 
and that 85% of patients had more than a 30% decline in PSA level within 3 months, while 76% of the 
patients had more than a 50% PSA decline at any time during the study [118]. 
Another analogue of 1,25D is paricalcitol which is related in chemical structure to vitamin D2. 
This analogue was tested in women receiving chemotherapy for metastatic breast cancer and the 
study documented that paricalcitol in combination with taxanes is safe and feasible [119]. This opens 
the possibility of larger clinical trials to assess health benefits of this analogue in women with breast 
cancer. 
7. Conclusion 
We can conclude there hasn’t been substantial benefit to date as to the use of 1,25D to treat 
cancers. The results of trials conducted so far show that neither 1,25D nor analogues are sufficient 
anti-cancer agents when used alone. In essence, response rates have been insufficient and variable 
and there haven’t been any dramatic increases in survival rates. In vitro and preclinical studies 
support the viewpoint that the various types of cancer are somewhat equally susceptible to the 
effects of 1,25D [120], and epidemiological studies clearly indicate that a correct level of serum 
vitamin D correlates with a low cancer incidence [109]. Careful analysis of these results may indicate 
that vitamin D is one of a few factors that correlate with the prevention of carcinogenesis. However, 
supplementing one of the factors, just vitamin D, may be not enough to slow down or cure the 
disease. Therefore, studies that aim to find accompanying factors, which act in concert with vitamin 
D, are necessary. Another possibility is that a low level of vitamin D or 25D is not causative for the 
above mentioned diseases. It should be also considered that such is a marker of poor health or a bad 
lifestyle. As yet, the verdict is uncertain in regard to the use of 1,25D analogues as an anticancer 
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agent particularly as the new analogues with negligible calcaemic action offer exciting prospects. 
These offer the possibility of achieving a more effective therapeutic dose with minimal side effects. 
When used in combination treatments they may deliver enhancement of the activities of other 
anti-cancer drugs or health benefits from their immune-modulatory actions. 
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